24 January 2024
24 January 2024
Due to its mechanism of action which retains muscle mass, Scholar Rock believe apitegromab could support treatment with GLP-1ra’s.
The development comes after the company raised $65m to expand clinical evidence for its neurostimulation system.
Initial results from the clinical trial indicate that AK-OTOF gene therapy restored hearing in patients with profound loss.
The trial will analyse PMC-309 as a monotherapy and in combination with Merck's KEYTRUDA in patients with advanced solid tumours.
NAYA’s acquisition includes Florida Biotechnologies’ AAV gene therapy for the treatment of a rare genetic disorder.
The company anticipates reporting the preliminary interim data from the ongoing trial in June 2024.
CBL-514’s efficacy, safety and tolerability will be analysed in the trial, following Australian approval.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
